Related Experiment Videos

Are patients with hyperlipidemia undertreated? Study of patients admitted to hospital with coronary events

Alan H Lipson1, Wendy M Fallis, Xiqui Wang

  • 1Victoria General Hospital, 2340 Pembina Highway, Winnipeg, MB R3T 2E8, Canada. alipson@vgh.mb.ca

Insights

Many high-risk patients with hyperlipidemia are not achieving their low-density lipoprotein cholesterol (LDL-C) goals, indicating undertreatment. This highlights opportunities to prevent cardiovascular events and reduce hospitalizations.

Area of Science:

  • Cardiology
  • Preventive Medicine
  • Public Health

Background:

  • Despite established guidelines, many patients with hyperlipidemia remain undertreated, failing to reach target lipid levels.
  • Coronary events continue to pose a significant health burden, necessitating effective risk management strategies.

Purpose of the Study:

  • To assess the pre-admission coronary risk and lipid levels of patients hospitalized with coronary events.
  • To identify the extent of undertreatment regarding low-density lipoprotein cholesterol (LDL-C) target levels in these patients.

Main Methods:

  • Retrospective chart review of 153 patients admitted with acute myocardial infarction, unstable angina, or acute coronary syndrome.
  • Calculation of each patient's 10-year coronary artery disease risk and categorization by risk status.
  • Recording and categorization of low-density lipoprotein cholesterol (LDL-C) levels based on Canadian guidelines.

Main Results:

  • Patients in low and moderate-risk categories had mean LDL-C levels significantly lower than target goals.
  • However, patients in the very high-risk category had a mean LDL-C level above the recommended goal, with 48.3% exceeding their target.
  • Only slightly over one-third of very high-risk patients were on lipid-lowering therapy.

Conclusions:

  • A significant proportion of community patients at very high risk for cardiovascular events are undertreated, not meeting LDL-C targets.
  • These findings underscore a critical need for improved management of hyperlipidemia to prevent patient morbidity and decrease cardiovascular hospitalizations.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...